



## King's Research Portal

DOI:

[10.1038/s41588-017-0013-8](https://doi.org/10.1038/s41588-017-0013-8)

[Link to publication record in King's Research Portal](#)

### *Citation for published version (APA):*

Luciano, M., Hagenaars, S., Davies, G., Hill, W. D., Clarke, T.-K., Shirali, M., Harris, S. E., Marioni, R., Liewald, D. C., Fawns-Ritchie, C., Adams, M. J., Howard, D., Lewis, C., Gale, C. R., McIntosh, A. M., & Deary, I. J. (2018). Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. *Nature Genetics*, 50(1), 6-11. <https://doi.org/10.1038/s41588-017-0013-8>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

1 Association analysis in over 329,000 individuals identifies 116 independent variants  
2 influencing neuroticism.

3

4 Michelle Luciano <sup>1\*</sup>, Saskia P Hagenaars <sup>1,2</sup>, Gail Davies <sup>1</sup>, W David Hill <sup>1</sup>, Toni-Kim Clarke  
5 <sup>1,3</sup>, Masoud Shirali <sup>1,3</sup>, Sarah E Harris <sup>1,4</sup>, Riccardo E Marioni <sup>1,4,5</sup>, David C Liewald<sup>1</sup>, Chloe  
6 Fawns-Ritchie <sup>1</sup>, Mark J Adams<sup>1,3</sup>, David M Howard<sup>1,3</sup>, Cathryn M Lewis<sup>2</sup>, Catharine R. Gale  
7 <sup>1,6</sup>, Andrew M McIntosh <sup>1,3,5</sup>, Ian J Deary <sup>1,5</sup>

8

9 <sup>1</sup> Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology,  
10 School of Philosophy, Psychology and Language Sciences, The University of Edinburgh,  
11 Edinburgh, UK

12 <sup>2</sup> MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,  
13 Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill,  
14 London, SE5 8AF, UK

15 <sup>3</sup> Division of Psychiatry, University of Edinburgh, Edinburgh, UK

16 <sup>4</sup> Centre for Genomic & Experimental Medicine, MRC Institute of Genetics & Molecular  
17 Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.

18 <sup>5</sup> Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetic  
19 and Experimental Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.

20 <sup>6</sup> MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

21

22 \*Corresponding author: [michelle.luciano@ed.ac.uk](mailto:michelle.luciano@ed.ac.uk), Department of Psychology, The  
23 University of Edinburgh, 7 George Square, EH8 9JZ, Edinburgh, UK

24

25

Neuroticism is a relatively stable personality trait characterised by negative emotionality (e.g., worry, guilt)<sup>1</sup>; twin study heritability ranges 30 to 50%<sup>2</sup>, and SNP-based heritability ranges 6 to 15%<sup>3-6</sup>. Increased neuroticism is associated with poorer mental and physical health<sup>7,8</sup>, translating to high economic burden<sup>9</sup>. Genome-wide association (GWA) studies of neuroticism have identified up to 11 genetic loci<sup>3,4</sup>. Here we report 116 significant independent loci from a GWA of neuroticism in 329,821 UK Biobank participants; 15 of these replicated at  $P < .00045$  in an unrelated cohort ( $N = 122,867$ ). Genetic signals were enriched in neuronal genesis and differentiation pathways, and substantial genetic correlations were found between neuroticism and depressive symptoms ( $r_g = .82$ ,  $SE = .03$ ), major depressive disorder (MDD;  $r_g = .69$ ,  $SE = .07$ ) and subjective wellbeing ( $r_g = -.68$ ,  $SE = .03$ ) alongside other mental health traits. These discoveries significantly advance our understanding of neuroticism and its association with MDD.

## **Main**

Understanding why people differ in neuroticism will provide an important contribution to understanding people's liability to poor mental health throughout the life course. The strong genetic correlation between neuroticism and mental health, especially anxiety and major depressive disorder<sup>10,11</sup>, means that exploring the genetic contribution to differences in neuroticism is one way to understand more about these common and burdensome, but aetiologically intractable illnesses. In the largest GWA study of major depressive disorder (MDD; 130,664 cases vs 330,470 controls), 44 independent genetic loci were identified<sup>12</sup>.

UK Biobank has health, medical and genetic information for over 500,000 individuals aged 39-73 years from the United Kingdom, assessed between 2006 and 2010<sup>13,14</sup>. We performed a GWA analysis of trait neuroticism in 329,821 unrelated White British adults (152,710 male (46.3%)) with high-quality genotype data (Online Methods). Neuroticism was

51 measured by the total score of the 12-item Eysenck Personality Questionnaire-Revised Short  
52 Form (EPQ-R-S) <sup>15</sup>; missing item data (ranging 1.8% to 4.7%) were imputed with reference  
53 to age and sex, and individuals with greater than 4 missing items were excluded  
54 (Supplementary Note, Supplementary Table 1 and Supplementary Fig. 1). For analysis, the  
55 score was residualized for the effects of age, sex, assessment centre, genotype batch, array,  
56 and 40 genetic principal components. This score was tested against 18,485,882 bi-allelic  
57 single nucleotide polymorphism (SNP) variants, based on the Haplotype Reference  
58 Consortium panel <sup>16</sup>, with a minor allele frequency  $\geq 0.0005$  and an information/imputation  
59 quality score of  $\geq 0.1$  under an additive model. The distribution of obtained versus expected  
60 results under the null hypothesis showed some genomic inflation, with a lambda of 1.15  
61 (quantile-quantile plot shown in Supplementary Fig. 2). Univariate linkage disequilibrium  
62 score (LDSC) regression <sup>17</sup> estimates indicated that 96.8% of this inflation was due to the  
63 presence of a large polygenic signal with the intercept being close to 1 (1.02, SE = .01). SNP-  
64 based heritability of neuroticism was estimated at .108 (SE=.005) using LDSC.

65         Genome-wide significance ( $P < 5 \times 10^{-8}$ ) was demonstrated for 10,353 genetic  
66 variants with a further 17,668 variants at a suggestive level ( $P < 1 \times 10^{-5}$ ) (Supplementary  
67 Table 2). The Manhattan plot is shown in Figure 1 and gene annotation for the significant  
68 SNPs in Supplementary Table 3. SNPs identified in previous neuroticism GWA studies were  
69 mostly significant in our sample (Supplementary Note and Supplementary Table 2) and  
70 substantial overlap with MDD SNPs (75%) and genes was found (Supplementary Note and  
71 Supplementary Table 4). The major histocompatibility complex (MHC) region has been  
72 previously linked to schizophrenia, a psychiatric comorbidity trait (including MDD) <sup>18,19</sup> and  
73 MDD <sup>12</sup>. It contained 3 significant independent genetic loci associated with neuroticism, two  
74 were in genes (*GABBR1*, *TNXB*) connected with schizophrenia <sup>20,21</sup>. The primary associated  
75 SNP, rs2021722, for schizophrenia <sup>18</sup>, was present in our study and nominally significant ( $P =$

76 9.42 x 10<sup>-5</sup>). Supplementary Figure 3 indicates the previous MHC associations in relation to  
77 our findings.

78 116 of the significant SNPs were independent ( $r^2 > 0.1$  and within 500kb of the  
79 significant index SNP); these lead SNPs are shown in Supplementary Table 5 with the  
80 number of associated SNPs, region size, and genes within the LD interval. 73 lead SNPs were  
81 located within genes, 5 were exonic (in *MSRA*, *NOS1*, *PINX1*, *ZCCHC14*, and *C12orf49*) and  
82 a further 2 were coding SNPs in *RPP21* (a missense mutation) and *AGBL1* (synonymous), 55  
83 were intronic and 10 were noncoding RNA variants; 42 were intergenic. For the 116  
84 independent SNPs, evidence of expression quantitative trait loci (eQTL) was explored using  
85 the GTEx database, 44 were eQTLs (Supplementary Table 5). A Regulome DB score was  
86 used to identify SNPs with a likely regulatory function. 33 of the 116 SNPs were included in  
87 the Regulome DB database and 8 of these had a score < 3, indicating that they are likely to be  
88 involved in gene regulation (Supplementary Table 5).

89 Replication of the significant association signals in UK Biobank was sought from the  
90 results of a GWA meta-analysis of neuroticism that we performed using 23andMe (N =  
91 59,206)<sup>22</sup> and the Genetics of Personality Consortium (GPC-2; N = 63,661)<sup>23</sup>. Of the 10,353  
92 genome-significant SNPs in UK Biobank, 10,171 were available in the replication cohorts,  
93 and 8,774 of these increased in significance when the replication cohorts were meta-analysed  
94 with UK Biobank. This indicated a consistent direction of allelic effect (Supplementary Table  
95 6).

96 INSERT FIGURE 1 ABOUT HERE

97  
98 Of the 116 independent associated SNPs, 111 were present in the replication cohort,  
99 with 51 nominally significant ( $P < .05$ ; Supplementary Table 5), and 15 at a Bonferroni-  
100 corrected level ( $P < .00045$ ; Table 1). One of these, *rs2953805*, was previously associated

with morning chronotype<sup>24</sup>, a trait relating to lower neuroticism<sup>25</sup> and showing allelic effects in the expected direction. The low replication rate (13.5%) at a strict corrected level reflects the finding that effect sizes are extremely small (up to .02 of a SD increase in neuroticism score per allele) and will thus require similarly large replication samples to confirm their effects. Figure 2a-c shows the regional association plot for chromosomes 8, 11 and 22 in which multiple genes were present in the associated LD region. Of the five chromosome 8 loci only one lead SNP tagged a well-known inversion, previously linked to neuroticism (Supplementary Note and Supplementary Fig. 4), although associations in the broad region had been attributed to the inversion<sup>4</sup> and so might cautiously be considered as a single locus.

All 69 genes located within the 15 replicated loci were classified in terms of their molecular function, biological process and protein class using the Protein Analysis Through Evolutionary Relationships Classification System which includes 14,710 protein families categorised into 76,032 functionally distinct subfamilies<sup>26</sup>. Supplementary Figure 4 shows that a large number of genes 1) coded for nucleic acid binding and transcription factors, 2) contributed to metabolic and cellular processes, and 3) had a role in binding and catalytic activity molecular functioning. Transcription factors, in particular, have been implicated in the aetiology of depression<sup>27,28</sup>, and miRNAs—which have been linked with anxiety<sup>29</sup> and depression<sup>30</sup>—might target genes with roles in binding (e.g., *POLR3H*). The PsyGeNET (v2.0) database showed that of the 69 genes, four have been associated with psychiatric disorder (Supplementary Table 7): *DRD2* (bipolar, depression, substance use/dependence, delirium), *EP300* (alcoholic intoxication), *TEF* (depression) and *MSRA* (schizophrenia). Variants in *CACNA1E* have been associated with cross-psychiatric disorder overlap and migraine<sup>18,31</sup>.

A GTEx database search for the 15 replicated SNPs showed that 9 were associated with significant regulation of 60 genes expressed in a variety of tissues (Supplementary Table

8). Of the 30 brain expression associations, half of these were in the cerebellum: 4 SNPs regulating 10 genes. Interestingly, MRI studies have shown associations between cerebellar volume and neuroticism, and cerebellar blood flow in response to negative emotional cues<sup>32,33</sup>. In the BRAINEAC search, all SNPs were identified as eQTLs in at least one brain region at a nominal significance level ( $P < .05$ ) and 10 were supported at a Bonferroni-corrected level of  $P < .0003$  (Supplementary Table 9). Of potential interest, rs7107356, a novel SNP in an intergenic region of chromosome 11, regulates *MTCH2* in the cerebellar cortex ( $P = 4.5 \times 10^{-6}$ ). *MTCH2* is involved in metabolic pathways and cell function<sup>34</sup> and variants of this gene have been associated with BMI<sup>35</sup>.

Gene-based analysis of the GWA results was performed using MAGMA<sup>36</sup>; 249 genes were significantly associated at a Bonferroni-corrected level ( $\alpha = 0.05 / 18,080$ ;  $P < 2.77 \times 10^{-6}$ ; Supplementary Table 10). Three of these were genes (*STH*, *HIST1H3J*, *HIST1H4L*) containing a single SNP. Of the replicated independent GWA SNPs that were in genes, the following significant genes were corroborated in the gene-based results: *CACNA1E*, *XKR6*, *MSRA*, *LINGO2*, *CELF4*, *ZC3H7B* and *BAIAP2*. SNP rs6981523, previously identified in 23andMe for neuroticism<sup>22</sup>, was an intergenic SNP near *XKR6*; this gene was the second most significant gene in our gene-based analysis ( $P = 6.55 \times 10^{-32}$ ). *L3MBTL2* and *CHADL*, wherein 23andMe's other significant SNP, rs9611519, resided, showed respective gene-based p-values of  $2.40 \times 10^{-6}$  and  $1.15 \times 10^{-6}$ .

Pathway analysis in MAGMA highlighted 5 significant gene ontology pathways (family-wise error  $P < 1.21 \times 10^{-6}$ ): neuron spine (cellular), homophilic cell adhesion via plasma membrane adhesion molecules (biological), neuron differentiation (biological), cell cell adhesion via plasma membrane adhesion molecules (biological), and neurogenesis (biological). See Table 2 for further details. Of note is the neurogenesis pathway, a hypothesis of which exists for depression (and to a lesser extent, anxiety) based on stress

reducing neurogenesis in the hippocampus and on the action of antidepressants on brain circuitry<sup>37,38</sup>. Further, variants in *PLXNA2*, potentially involved in adult neurogenesis, have been associated with anxiety and neuroticism<sup>39</sup>. Cell adhesion molecules have been implicated in neuropsychiatric disorder<sup>40</sup>, and protocadherins specifically with neuroticism and risk of mood disorder<sup>41</sup>, which supports the importance of cell adhesion pathways. A further gene-set analysis of genes expressing proteins that can bind to anti-depressant drug molecules was significant ( $P = .005$ ) re-affirming the dependency of neuroticism and depression on shared biological pathways. This is consistent, for example, with findings for *CRHRI* (highlighted in our SNP and gene-based analysis), a gene involved in normal hormonal responses to stress (the glucocorticoid pathway being a relevant and well-known target) and associated with anxiety, depression and neuroticism<sup>3,42,43</sup>. That genes influencing neuroticism reveal pathways involved in currently prescribed and effective antidepressant action suggests that neuroticism could be a potentially useful clinical stratifying factor for effective antidepressant action. There may also be clinical utility in knowing a person's level of neuroticism after the occurrence of a stressful life event and therefore pre-empting onset of depression via drug therapy in those high in neuroticism. Because our GWA of neuroticism reveals signals associated with the known biological action of existing antidepressants, it may be useful as a means of discovering (or re-purposing) new pharmacological interventions for MDD.

LD score regression<sup>44</sup> was used to estimate the genetic correlation between neuroticism and a variety of health traits (Supplementary Tables 11 and 12). The strongest correlation was observed for depressive symptoms ( $r_g = .82$ ,  $SE = .03$ ). Major depressive disorder, subjective wellbeing, and tiredness showed moderate-to-strong correlations (.62-.69). The stronger correlation for depressive symptoms than depressive disorder might be indicative of improved sensitivity of continuous versus dichotomous traits but might also



point to inventory item overlap (greater conceptual similarity) for depressive symptoms and/or noise in MDD diagnosis. Genetic correlations with neuroticism were moderate for self-rated health (.41), moderate-to-low for schizophrenia, ADHD, anorexia nervosa and educational attainment ( $\sim|.20|$ ), and low for bipolar disorder and smoking status ( $|.11|$ ). The genetic correlation of one between Eysenck neuroticism and other neuroticism scales (used by 23andMe and the GPC) confirms that GWA meta-analysis based on different measurement instruments is valid. Mendelian randomization was used to determine whether the genetic correlation between neuroticism and non-psychiatric variables (less likely to be influenced by pleiotropy), smoking status and educational attainment, represented a causal relationship from neuroticism. For smoking status, the beta of 0.23 was significant in the inverse variance weighted model ( $P = .00002$ ) which is preferred in the presence of heterogeneity ( $P = .001$ ); the MR Egger regression did not show significant directional pleiotropy (intercept = 0.02,  $P = .10$ ) thus supporting a causal relationship. For educational attainment, the beta of -0.09 was significant ( $P = 8.35 \times 10^{-6}$ ) in the inverse variance weighted model (heterogeneity  $P = 5.87 \times 10^{-7}$ ), with no evidence of directional pleiotropy (intercept = 0,  $P = .23$ ). Although theoretically less plausible, the reverse causal direction should be investigated in UK Biobank once a large number of significant SNPs influencing smoking status and educational attainment have been estimated in non-overlapping samples.

Polygenic profile analyses based on the SNP inclusion threshold with the optimal signal-to-noise ratio ( $P < .05$ ) indicated that the neuroticism polygenic score explained 2.79% of the variance in neuroticism ( $\beta = .19$ ,  $P = 2.65 \times 10^{-47}$ ) and 0.8% of the variance in depression status ( $OR = 1.25$ ,  $P = 1.53 \times 10^{-8}$ ) in Generation Scotland (GS;  $N = 7,388$ )<sup>45</sup>. Results for polygenic scores in GS based on other SNP significance inclusion thresholds (0.01, 0.05, 0.1, 0.5 and 1) from the UK Biobank GWA can be found in Supplementary Table 13.

The combination, in UK Biobank, of a large ethnically homogenous sample and a well-validated neuroticism scale has afforded the discovery of 15 stringently replicated genetic loci that influence neuroticism levels, four of them novel. Most lead variants were associated with gene regulation, with half of these expressed in the brain; single variant and gene associations overlapped substantially with MDD findings, and genes in antidepressant-targeted pathways were over-represented. There was also support for neuroticism having causal effects on socio-economic markers. These discoveries promise paths to understand the mechanisms whereby some people become depressed, and of broader human differences in happiness, and they are a resource for those seeking novel drug targets for major depression. After millennia in which scholars and researchers have sought the sources of individual differences in proneness to dysphoria <sup>46</sup>, the present study adds significantly to explaining the (genetic) anatomy of melancholy.

#### **URLs**

UK Biobank Resource: <http://www.ukbiobank.ac.uk>  
BGENIE: <https://jmarchini.org/bgenie/>  
BRAINEAC: <http://www.braineac.org/>  
Druggable genome: <http://dgidb.genome.wustl.edu/>  
Genotype-Tissue Expression Portal: <http://www.gtexportal.org>  
Gene Ontology: <http://geneontology.org>  
GPC-2 Summary Statistics: <http://www.tweelingenregister.org/GPC/>  
Linkage Disequilibrium Score Regression: <https://github.com/bulik/ldsc/wiki>  
METAL: <http://csg.sph.umich.edu/abecasis/metal/index.html>  
PANTHER: <http://pantherdb.org/>  
PLINK V2: <https://www.cog-genomics.org/plink2>

PsyGeNet: <http://www.psygenet.org/web/PsyGeNET/menu/home>

Regulome Database: <http://www.regulomedb.org/>

## **Acknowledgements**

This research has been conducted using the UK Biobank Resource (Application Nos. 10279 and 4844). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Ethical approval for the GS:SFHS study was obtained from the Tayside Committee on Medical Research Ethics ( 05/S1401/89 Tayside Committee on Medical Research Ethics A). We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. This work was supported by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1); funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Medical Research Council (MRC) is gratefully acknowledged. This report represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. W.D.H. is supported by a grant from Age UK (Disconnected Mind Project). A.M.M. and I.J.D. are supported by funding from a Wellcome Trust Strategic Award (104036/Z/14/Z).

## **Author Disclosure**

IJD was a participant in UK Biobank. The other authors declare no conflict of interest.

251

252 **Author Contributions**

253 M.L. drafted the manuscript with contributions from W.D.H. and I.J.D. G.D., D.C.L.,  
254 R.E.M., M.J.A. and D.M.H. performed quality control of UK Biobank data and/or Generation  
255 Scotland. M.L, G.D, S.P.H., and M.S. analysed the data. T-K.C., C.F-R., W.D.H. and S.E.H.  
256 performed/assisted with downstream analysis. C.R.G, C.M.L., and A.M.M provided critical  
257 comments on the manuscript draft and analysis. M.L. and I.J.D. co-ordinated the work. All  
258 authors commented on and approved the manuscript.

259

260

## References for Main text

1. Matthews, G., Deary, I.J. & Whiteman, M.C. *Personality Traits*, (Cambridge University Press, 2009).
2. Vukasovic, T. & Bratko, D. Heritability of personality: A meta-analysis of behavior genetic studies. *Psychological Bulletin*.**141**, pp (2015).
3. Smith, D.J. *et al.* Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci. *Mol Psychiatry* **21**, 749-57 (2016).
4. Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat Genet* **48**, 624-33 (2016).
5. Power, R.A. & Pluess, M. Heritability estimates of the Big Five personality traits based on common genetic variants. *Transl Psychiatry* **5**, e604 (2015).
6. Vinkhuyzen, A.A. *et al.* Common SNPs explain some of the variation in the personality dimensions of neuroticism and extraversion. *Transl Psychiatry* **2**, e102 (2012).
7. Kubzansky, L.D., Martin, L.T. & Buka, S.L. Early manifestations of personality and adult health: a life course perspective. *Health Psychol* **28**, 364-72 (2009).
8. Strickhouser, J.E., Zell, E. & Krizan, Z. Does Personality Predict Health and Well-Being? A Metasynthesis. *Health psychology: official journal of the Division of Health Psychology, American Psychological Association* (2017).
9. Cuijpers, P. *et al.* Economic costs of neuroticism: a population-based study. *Arch Gen Psychiatry* **67**, 1086-1093 (2010).
10. Few, L.R. *et al.* Genetic variation in personality traits explains genetic overlap between borderline personality features and substance use disorders. *Addiction* **109**, 2118-27 (2014).

- 286 11. Kendler, K.S., Gatz, M., Gardner, C.O. & Pedersen, N.L. Personality and major  
287 depression: a Swedish longitudinal, population-based twin study. *Arch Gen*  
288 *Psychiatry* **63**, 1113-20 (2006).
- 289 12. Wray, N.R. & Sullivan, P.F. Genome-wide association analyses identify 44 risk  
290 variants and refine the genetic architecture of major depression. *bioRxiv* (2017).
- 291 13. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a  
292 wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779  
293 (2015).
- 294 14. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants.  
295 *bioRxiv* (2017).
- 296 15. Eysenck, S.B., Eysenck, H.J. & Barrett, P. A revised version of the psychoticism  
297 scale. *Personality and individual differences* **6**, 21-29 (1985).
- 298 16. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation.  
299 *Nat Genet* **48**, 1279-1283 (2016).
- 300 17. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from  
301 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295 (2015).
- 302 18. Cross-Disorder Group of the Psychiatric Genomics, C. Identification of risk loci with  
303 shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*  
304 **381**, 1371-1379 (2013).
- 305 19. Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component  
306 4. *Nature* **530**, 177-183 (2016).
- 307 20. Hegyi, H. GABBR1 has a HERV-W LTR in its regulatory region – a possible  
308 implication for schizophrenia. *Biology Direct* **8**, 5-5 (2013).

- 309 21. Wei, J. & Hemmings, G.P. TNXB locus may be a candidate gene predisposing to  
310 schizophrenia. *American Journal of Medical Genetics Part B: Neuropsychiatric*  
311 *Genetics* **125B**, 43-49 (2004).
- 312 22. Lo, M.-T. *et al.* Genome-wide analyses for personality traits identify six genomic loci  
313 and show correlations with psychiatric disorders. *Nat Genet* **49**, 152-156 (2017).
- 314 23. Genetics of Personality, C. *et al.* Meta-analysis of Genome-wide Association Studies  
315 for Neuroticism, and the Polygenic Association With Major Depressive Disorder.  
316 *JAMA Psychiatry* **72**, 642-50 (2015).
- 317 24. Hu, Y. *et al.* GWAS of 89,283 individuals identifies genetic variants associated with  
318 self-reporting of being a morning person. *Nat Commun* **7**, 10448 (2016).
- 319 25. Duggan, K.A., Friedman, H.S., McDevitt, E.A. & Mednick, S.C. Personality and  
320 Healthy Sleep: The Importance of Conscientiousness and Neuroticism. *PLOS ONE* **9**,  
321 e90628 (2014).
- 322 26. Mi, H., Muruganujan, A. & Thomas, P.D. PANTHER in 2013: modeling the  
323 evolution of gene function, and other gene attributes, in the context of phylogenetic  
324 trees. *Nucleic Acids Research* **41**, D377-D386 (2013).
- 325 27. Sulser, F. The role of CREB and other transcription factors in the pharmacotherapy  
326 and etiology of depression. *Annals of Medicine* **34**, 348-356 (2002).
- 327 28. Wang, H. *et al.* Forkhead box O transcription factors as possible mediators in the  
328 development of major depression. *Neuropharmacology* **99**, 527-537 (2015).
- 329 29. Malan-Müller, S., Hemmings, S.M.J. & Seedat, S. Big Effects of Small RNAs: A  
330 Review of MicroRNAs in Anxiety. *Molecular Neurobiology* **47**, 726-739 (2013).
- 331 30. Dwivedi, Y. Emerging role of microRNAs in major depressive disorder: diagnosis  
332 and therapeutic implications. *Dialogues in Clinical Neuroscience* **16**, 43-61 (2014).

- 333 31. Ambrosini, A. *et al.* Possible Involvement of the CACNA1E Gene in Migraine: A  
334 Search for Single Nucleotide Polymorphism in Different Clinical Phenotypes.  
335 *Headache: The Journal of Head and Face Pain* **57**, 1136-1144 (2017).
- 336 32. Schraa-Tam, C.K.L. *et al.* fMRI activities in the emotional cerebellum: a preference  
337 for negative stimuli and goal-directed behavior. *The Cerebellum* **11**, 233-245 (2012).
- 338 33. Schutter, D.J.L.G., Koolschijn, P.C.M.P., Peper, J.S. & Crone, E.A. The Cerebellum  
339 Link to Neuroticism: A Volumetric MRI Association Study in Healthy Volunteers.  
340 *PLOS ONE* **7**, e37252 (2012).
- 341 34. Grinberg, M. *et al.* Mitochondrial carrier homolog 2 is a target of tBID in cells  
342 signaled to die by tumor necrosis factor alpha. *Mol Cell Biol* **25**, 4579-90 (2005).
- 343 35. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity  
344 biology. *Nature* **518**, 197-206 (2015).
- 345 36. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: Generalized  
346 Gene-Set Analysis of GWAS Data. *PLoS Computational Biology* **11**(2015).
- 347 37. Lucassen, P.J., Oomen, C.A., Schouten, M., Encinas, J.M. & Fitzsimons, C.P. Chapter  
348 8 - Adult Neurogenesis, Chronic Stress and Depression A2 - Canales, Juan J. in *Adult*  
349 *Neurogenesis in the Hippocampus* 177-206 (Academic Press, San Diego, 2016).
- 350 38. Schoenfeld, T.J. & Cameron, H.A. Adult Neurogenesis and Mental Illness.  
351 *Neuropsychopharmacology* **40**, 113-128 (2015).
- 352 39. Wray, N.R., James, M.R., Mah, S.P. & et al. Anxiety and comorbid measures  
353 associated with plxna2. *Arch Gen Psychiatry* **64**, 318-326 (2007).
- 354 40. Redies, C., Hertel, N. & Hübner, C.A. Cadherins and neuropsychiatric disorders.  
355 *Brain Research* **1470**, 130-144 (2012).



- 356 41. Chang, H. *et al.* The protocadherin 17 gene affects cognition, personality, amygdala  
357 structure and function, synapse development and risk of major mood disorders. *Mol*  
358 *Psychiatry* (2017).
- 359 42. DeYoung, C.G., Cicchetti, D. & Rogosch, F.A. Moderation of the association  
360 between childhood maltreatment and Neuroticism by the corticotropin-releasing  
361 hormone receptor 1 gene. *Journal of child psychology and psychiatry, and allied*  
362 *disciplines* **52**, 898-906 (2011).
- 363 43. Binder, E.B. & Nemeroff, C.B. The CRF system, stress, depression and anxiety –  
364 insights from human genetic studies. *Mol Psychiatry* **15**, 574-588 (2010).
- 365 44. Bulik-Sullivan, B.K. *et al.* An atlas of genetic correlations across human diseases and  
366 traits. *Nat Genet* **47**, 1236-41 (2015).
- 367 45. Smith, B.H. *et al.* Cohort Profile: Generation Scotland: Scottish Family Health Study  
368 (GS:SFHS). The study, its participants and their potential for genetic research on  
369 health and illness. *International Journal of Epidemiology* **42**, 689-700 (2013).
- 370 46. Burton, R. The Anatomy of Melancholy. (eds Faulkner, T.C., Kiessling, N.K. & Blair,  
371 R.L.) (Oxford University Press, 1989 ).

372

373 **Figure Legends for Main Text**

374 Figure 1. GWA results for neuroticism in 329,821 UK Biobank individuals.

375

376 Figure 2. Regional association plot for suggestive/significant signals in UK Biobank on a)

377 chromosome 8p (site of the inversion polymorphism), b) chromosome 11, and c)

378 chromosome 22. The SNP association p-value is shown on the y-axis and the SNP position

379 (with gene annotation) appears on the x-axis; for each SNP, the strength of LD with the lead

380 SNP is colour coded based on its  $r^2$ . Plots were produced in LocusZoom.

381



383 **Table 1. Fifteen independent SNPs associated with neuroticism in UK Biobank most strongly replicated (with consistent allelic effect) in**  
384 **the meta-analysis of 23andMe and the GPC cohorts. Bolded genes were significant in the gene-based tests.**

Chr	SNP	MAF	Discovery P-value (N=329,821)	Replication P-value (N=122,867)	Nearest Gene	Distance to Gene	Genes within Range	Significant in Previous GWA Studies
1	rs169235	.25	$3.97 \times 10^{-9}$	2.55E-05	<b>CACNA1E</b> **	0		
5	rs1422192 <sup>^</sup>	.17	$1.68 \times 10^{-9}$	6.54E-07	<i>LINC00461</i>	0	<b>MEF2C</b> **	
8* <sup>‡</sup>	rs2921036	.49	$8.04 \times 10^{-26}$	3.27E-07	.	.	<b>CLDN23, ERI1**</b> , <b>MFHAS1</b> **, <b>SGK223</b>	
8* <sup>‡</sup>	rs2953805	.47	$3.02 \times 10^{-22}$	1.26E-08	<i>U3</i>	1292	<b>CLDN23, ERI1**</b> , <b>MFHAS1</b> **, <b>PPP1R3B</b>	Morning vs Evening Chronotype <sup>24</sup>
8* <sup>‡</sup>	rs6982308	.49	$6.46 \times 10^{-21}$	2.26E-08	<b>MSRA</b> **	0		
8* <sup>‡</sup>	rs7005884	.45	$1.92 \times 10^{-23}$	1.34E-07	<b>XKR6</b>	0	<b>C8orf74, PINX1**</b> , <b>PRSS55**</b> , <b>RP1L1</b> , <b>SOX7**</b> , <b>XKR6</b>	
8* <sup>‡</sup>	rs10097870	.47	$2.18 \times 10^{-24}$	6.51E-07	<i>LINC00208</i>	5665	<b>BLK**</b> , <b>CTSB**</b> , <b>DEFB134**</b> , <b>DEFB135</b> , <b>DEFB136</b> , <b>FAM167A**</b> , <b>FDFT1</b> , <b>GATA4</b> , <b>LOC100133267</b> , <b>MTMR9</b> , <b>NEIL2</b> , <b>SLC35G5</b> , <b>XKR6</b>	
9	rs1521732	.37	$2.91 \times 10^{-9}$	4.01E-06	<b>LINGO2</b>	0		
9	rs72694263	.08	$2.12 \times 10^{-8}$	0.000237	.	.		
11*	rs7107356	.50	$1.52 \times 10^{-12}$	1.34E-05	<b>AGBL2</b>	4973	<b>ACP2, AGBL2, C1QTNF4</b> , <b>CELF1</b> , <b>DDB2**</b> , <b>FAM180B</b> , <b>FNBP4**</b> , <b>KBTD4</b> , <b>MADD**</b> , <b>MTCH2**</b> , <b>MYBPC3</b> , <b>NDUFS3</b> , <b>NR1H3</b> , <b>NUP160**</b> , <b>PSMC3</b> , <b>PTPMT1</b> , <b>RAPSN</b> , <b>SLC39A13**</b> ,	Neuroticism <sup>4</sup>

							<i><b>SPI1</b></i>
11*	rs7111031	.36	$1.06 \times 10^{-15}$	0.000215	.	.	<i><b>DRD2</b></i>
15*	rs7175083	.48	$1.16 \times 10^{-9}$	0.000297	<i><b>LINGO1</b></i>	0	
17	rs7502590	.15	$2.61 \times 10^{-11}$	0.000146	<i><b>BAIAP2</b></i>	0	<i><b>AATK, BAIAP2</b></i>
18*	rs11082011	.34	$1.25 \times 10^{-16}$	2.05E-06	<i><b>CELF4</b></i>	0	
22*	rs11090045	.30	$8.04 \times 10^{-13}$	5.40E-07	<i><b>ZC3H7B**</b></i>	0	<i><b>ACO2, C22orf46, CHADL, CSDC2**, DESI1, EP300, L3MBTL2**, MEI1, NHP2L1, PHF5A, PMM1, POLR3H, RANGAP1**, RBX1, TEF**, TOB2, XRCC6, ZC3H7B**</b></i>

385 ^ Genotyped SNP

386 † Located in Inversion Region

387 \* Broad region implicated in previous studies <sup>4,22,45</sup>

388 \*\* Regulated gene expressed in brain

389

390 **Table 2. Significant gene ontology pathways for neuroticism in UK Biobank**

Pathway	Number of genes	Beta	SE	P-value	Corrected P	Definition
Neuron Spine	147	0.560	0.107	$7.77 \times 10^{-8}$	0.0282	A small membranous protrusion, often ending in a bulbous head and attached to the neuron by a narrow stalk or neck.
Homophilic Cell Adhesion Via Plasma Membrane Adhesion Molecules	115	0.490	0.0938	$8.81 \times 10^{-8}$	0.0289	The attachment of a plasma membrane adhesion molecule in one cell to an identical molecule in an adjacent cell.
Neuron Differentiation	1341	0.145	0.0288	$2.36 \times 10^{-7}$	0.0357	The process in which a relatively unspecialized cell acquires specialized features of a neuron.
Cell Cell Adhesion Via Plasma Membrane Adhesion Molecules	828	0.183	0.0364	$2.72 \times 10^{-7}$	0.0372	The attachment of one cell to another cell via adhesion molecules that are at least partially embedded in the plasma membrane.
Neurogenesis	195	0.419	0.0859	$5.35 \times 10^{-7}$	0.0439	Generation of cells within the nervous system

## Online Methods

### Genome-wide association analysis in UK Biobank

An imputed dataset, including >92 million variants, referenced to the UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference Consortium (HRC) panels was available in UK Biobank. The current analysis includes only those SNPs available in the HRC reference panel<sup>47</sup>. Quality control filters were applied (see Supplementary Note) which resulted in 18,485,882 imputed SNPs for analysis in 329,821 individuals. The GWA of neuroticism was conducted using BGENIE<sup>48</sup>, a program specifically developed to analyse UK Biobank data in a fast and efficient manner. Further information can be found at the following URL: <https://jmarchini.org/bgenie/>. A linear SNP association model was tested which accounted for genotype uncertainty. Neuroticism was pre-adjusted for age, sex, genotyping batch, genotyping array, assessment centre, and 40 principal components to speed up analysis.

The number of independent signals from the GWA analysis was determined using LD-clumping in PLINK v1.90b3i<sup>49</sup> (see URLs). The LD structure was based on SNPs with a  $p\text{-value} < 1 \times 10^{-3}$  that were extracted from the imputed genotypes. Index SNPs were identified ( $P < 5 \times 10^{-8}$ ) and clumps were formed for SNPs with  $P < 1 \times 10^{-5}$  that were in LD ( $r^2 > 0.1$ ) and within 500kb of the index SNP. SNPs were assigned to no more than one clump.

### Meta-analysis of GWA Results

Two meta-analyses were performed. Firstly, to check for replication of the significant ( $P < 5 \times 10^{-8}$ ) GWA signals in UK Biobank, results from a meta-analysis of 23andme<sup>50</sup> (the full GWA summary statistics were made available from 23andMe) and the Genetics of Personality Consortium (GPC-2)<sup>51</sup> (the full GWA summary statistics were publicly available

see URLs ) were used. This meta-analysis was conducted using METAL<sup>52</sup> and due to the lack of phenotype harmonisation across the cohorts, a sample size weighted meta-analysis was preferred. A second meta-analysis of UK Biobank and the replication cohorts was performed using the same method, but only for the SNPs that were significant in UK Biobank.

#### Genome-wide Gene-based Analysis

Gene-based analysis of neuroticism was performed using MAGMA<sup>53</sup>, which provides gene-based statistics derived using the results of the GWA analysis. Genetic variants were assigned to genes based on their position according to the NCBI 37.3 build, with no additional boundary placed around the genes. This resulted in a total of 18,080 genes being analysed. The European panel of the 1000 Genomes data (phase 1, release 3) was used as a reference panel to account for linkage disequilibrium. A genome-wide significance threshold for gene-based associations was calculated using the Bonferroni method ( $\alpha=0.05/18,080$ ;  $P < 2.77 \times 10^{-6}$ ).

#### Functional annotation and gene expression

For the 116 independent genome-wide significant SNPs identified by LD clumping, evidence of expression quantitative trait loci (eQTL) and functional annotation were explored using publicly available online resources. The Genotype-Tissue Expression Portal (GTEx) (see URLs) was used to identify eQTLs associated with the SNPs. Functional annotation was investigated using the Regulome DB database<sup>54</sup> (see URLs). Further to GTEx searches, we investigated whether any of the 15 replicated SNPs were brain expression quantitative loci (eQTLs) by entering them into the brain eQTL database BRAINEAC (see URLs), which



contains gene expression data across ten brain regions (cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, temporal cortex, thalamus and intralobular white matter). The genes located in the region of replicated independent loci were investigated for protein function using the PANTHER database (Protein ANalysis THrough Evolutionary Relationships, see URLs ) which stores data on the evolution and function of protein-coding genes from sequenced genomes of diverse species<sup>55</sup>, our focus here on homo sapiens. Uncharacterized gene function is predicted via phylogenetic branching information and the resource enables biological pathway annotation.

#### Pathway Analysis

Biological pathway analysis was performed on the gene-based analysis results. This gene-set enrichment analysis was conducted utilising gene-annotation files from the Gene Ontology (GO) Consortium (see URLs)<sup>56</sup> taken from the Molecular Signatures Database (MSigDB) v5.2. The GO consortium includes gene-sets for three ontologies; molecular function, cellular components and biological function. This annotation file consisted of 5,917 gene-sets which were corrected for multiple testing correction using the MAGMA default setting correcting for 10,000 permutations.

To determine whether the genetic targets of antidepressants were enriched for neuroticism we performed a competitive gene-set analysis using MAGMA. Gene sets corresponding to the Anatomical Therapeutic Chemical Classification System code N06A *Antidepressants* (within the *Psychoanaleptics* class) were downloaded (see URLs). This resulted in a set of 110 unique genes corresponding to those that are the targets of the antidepressants. Enrichment for neuroticism was tested against a set of 5483 ‘druggable’ autosomal genes (see URLs), that is, they code for proteins which can bind to drug-like

molecules. Of the 110 antidepressant genes 86 were found amongst the 5483 druggable genes.

#### Linkage Disequilibrium Score Regression

Univariate Linkage disequilibrium Score (LDSC) regression<sup>57</sup> was used to test for residual stratification in our GWAS summary statistics and to derive a heritability estimate. An LD regression was performed by regressing the GWA test statistics ( $\chi^2$ ) on to each SNP's LD score (the sum of squared correlations between the minor allele frequency count of a SNP with the minor allele frequency count of every other SNP). This regression allows for the estimation of heritability from the slope, and a means to detect residual confounders, the intercept. The percentage inflation in the test statistic due to polygenic signal can be derived by subtracting the LDSC ratio ((intercept - 1)/(mean  $\chi^2$  - 1)), which represents inflation due to population stratification and other confounding, from 1 and multiplying by 100. Bivariate LDSC regression<sup>58</sup> was used to derive genetic correlations between neuroticism and 18 psychiatric and physical health phenotypes (see Supplementary Table 11). For Alzheimer's disease, a 500-kb region surrounding *APOE* was excluded and the analysis re-run (Alzheimer's disease (500kb)). The genetic correlation between neuroticism as measured by different inventories was also estimated. Further details, including source of GWA summary statistics can be found in the Supplementary Note. Sample overlap could not be controlled for in the LDSC analyses because the exact overlap between the UK Biobank data and the health traits was unknown. In such a case, constraining the intercept to a 'wrong' value could lead to biased estimates. Any sample overlap in the present analyses will only affect the intercept of the regression and could lead to inflated standard errors, but will not affect the genetic correlation<sup>12</sup>.

## Mendelian Randomization

Two sample Mendelian Randomization (MR) was performed using the TwoSampleMR<sup>59</sup> package implemented in R. GWA summary statistics from the GWA of smoking status in 74,053 Europeans<sup>60</sup> was used to create outcome data for the MR between neuroticism and smoking status. 77 independent SNPs associated with neuroticism were available in the smoking status GWA summary data to test for a causal effect of neuroticism on smoking status. There were no significant SNP signals for smoking status to test the reverse causation model. GWA summary statistics from the GWA of educational attainment in 126,559 Caucasians<sup>61</sup> was used to create outcome data for the MR between neuroticism and educational attainment. 75 independent SNPs associated with neuroticism were available in the educational attainment GWA summary data to test for a causal effect of neuroticism on educational attainment. There were too few significant SNPs available for educational attainment to test for a causal effect of educational attainment on neuroticism. Sensitivity analyses were performed to test for heterogeneity and a further test for horizontal pleiotropy was carried out.

## Polygenic Prediction into Generation Scotland

Polygenic profile analyses were performed to predict neuroticism and depression status in Generation Scotland (GS)<sup>62</sup>. Polygenic profiles were created in PRSice<sup>63</sup> using the UK Biobank neuroticism SNP-based association results, for 7,388 unrelated individuals in GS. SNPs with a MAF <0.01 were removed prior to creating the polygenic profiles. Clumping was used to obtain SNPs in linkage disequilibrium with an  $r^2 < 0.25$  within a 250kb window. Individuals were removed from GS if they had contributed to both UK Biobank and GS (n = 302). Polygenic profile scores were created based on the significance of the association in UK Biobank with the neuroticism phenotype, at p-value thresholds of 0.01, 0.05, 0.1, 0.5 and

1 (all SNPs). Linear regression models were used to examine the associations between the polygenic profile and neuroticism score in GS, adjusting for age at measurement, sex and the first 10 genetic principal components to adjust for population stratification. Logistic regression models were used to examine depression status, adjusting for the same covariates as in the neuroticism models. The false discovery rate (FDR) method was used to correct for multiple testing across the polygenic profiles for neuroticism at all five thresholds<sup>64</sup>.

### Data Availability

The GWA results generated by this analysis are publicly available at <http://www.ccace.ed.ac.uk>.

### References for Online Methods

47. Haplotype Reference, C. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279-1283 (2016).
48. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv* (2017).
49. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* **4**, 7 (2015).
50. Lo, M.-T. *et al.* Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. *Nat Genet* **49**, 152-156 (2017).
51. Genetics of Personality, C. *et al.* Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. *JAMA Psychiatry* **72**, 642-50 (2015).
52. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2 (2010).

539 53. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: Generalized  
540 Gene-Set Analysis of GWAS Data. *PLoS Computational Biology* **11**(2015).

541 54. Boyle, A.P. *et al.* Annotation of functional variation in personal genomes using  
542 RegulomeDB. *Genome research* **22**, 1790-1797 (2012).

543 55. Mi, H. *et al.* PANTHER version 11: expanded annotation data from Gene Ontology  
544 and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids*  
545 *Research* **45**, D183-D189 (2017).

546 56. Gene Ontology, C. Expansion of the Gene Ontology knowledgebase and resources.  
547 *Nucleic acids research* **45**, D331-D338 (2017).

548 57. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from  
549 polygenicity in genome-wide association studies. *Nature genetics* **47**, 291-295 (2015).

550 58. Bulik-Sullivan, B.K. *et al.* An atlas of genetic correlations across human diseases and  
551 traits. *Nat Genet* **47**, 1236-41 (2015).

552 59. Hemani, G. *et al.* MR-Base: a platform for systematic causal inference across the  
553 phenome using billions of genetic associations. *bioRxiv* (2016).

554 60. Genome-wide meta-analyses identify multiple loci associated with smoking behavior.  
555 *Nat Genet* **42**, 441-447 (2010).

556 61. Rietveld, C.A. *et al.* GWAS of 126,559 individuals identifies genetic variants  
557 associated with educational attainment. *science* **340**, 1467-1471 (2013).

558 62. Smith, B.H. *et al.* Cohort Profile: Generation Scotland: Scottish Family Health Study  
559 (GS:SFHS). The study, its participants and their potential for genetic research on  
560 health and illness. *International Journal of Epidemiology* **42**, 689-700 (2013).

561 63. Euesden, J., Lewis, C.M. & O'Reilly, P.F. PRSice: polygenic risk score software.  
562 *Bioinformatics* **31**, 1466-1468 (2014).

563 64. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and  
564 powerful approach to multiple testing. *Journal of the royal statistical society. Series B*  
565 *(Methodological)*, 289-300 (1995).

566

# Genome-wide association results for neuroticism in UK Biobank



